

ROGER M. LYONS, MD, FACP

PUBLICATIONS

1. Goldenberg, GJ, Lyons, RM, Lepp, JA, and Vanstone, CL. Sensitivity to nitrogen mustard as a function of transports activity and proliferative rate in L5178Y lymphoblasts. *Cancer Res.* 1971;31:1616-1919.
2. Lyons, RM and Goldenberg, GJ. Active transport of nitrogen mustard and choline by normal and leukemic human lymphoid cells. *Cancer Res.* 1972;32:1679-1695.
3. Lyons, RM, Chaplin, H., Tillack, TW, and Majerus, PW. Gamma heavy chain disease: rapid, sustained response to cyclophosphamide and prednisone. *Blood.* 1975: 46:1-9.
4. Lyons, RM, Stanford, N, Majerus, PW. Thrombin-induced protein phosphorylation in human platelets. *J Clin Invest.* 1975;56:924-934.
5. Fisher, BL, Lyons, RM, and Sears, DA. Development of chronic myelocytic leukemia during the course of acute lymphocytic leukemia in an adult. *Am J Hematol.* 1977;2(3):291-297.
6. Rutstein, JE, Holahan, JF, Lyons, RM, and Pope, RM. Rheumatoid factor interference with the latex agglutination test for fibrin degradation products. *J Lab Clin Med.* 1978: 92:529-535.
7. Lyons, RM, Atherton, RM. Characterization of a platelet protein phosphorylated during the thrombin induced release reaction. *Biochemistry.* 1979;18:544-552.
8. Lyons, RM, Shaw, JO. Interaction of Ca²⁺ and protein phosphorylation in the rabbit platelet release reaction. *J Clin Invest.* 1980;65:252-255.
9. George, JN, Lyons, RM, and Morgan, RM. Membrane changes associated with platelet activation: exposure of actin on the platelet surface following thrombin induced secretions. *J Clin Invest.* 1980;66:1-9.
10. Lyons, RM. Compartmentalization of adenosine 3': 5'' -monophosphate - binding proteins in human platelets. *Thrombosis Res.* 1980;19:317-322.
11. Shaw, JO, Lyons, RM. Requirements for different Ca²⁺ pools in the activation of rabbit platelets: I. release reaction and protein phosphorylation. *Biochem Biophys Acta.* 1982;714:492-499.
12. Shaw, JO and Lyons, RM. Requirements for different Ca²⁺ pools in the activation of rabbit platelets: II. phospholipase activity. *Biochem Biophys Acta.* 1982;714: 500-504.

13. Shaw, JO, Brodersen, I, Lyons, RM. Extra and intracellular Ca²⁺ requirements for lysosomal enzyme secretion in human neutrophils. *Agents and Actions*. 1982;12:328-332.
14. Lieu, Y, Lyons, RM, McDonagh, J. An abnormal plasminogen with a more cathodic migration: decreased activation and associated thrombosis. *Thrombosis and Hemostasis*. 1988;59:49-53.
15. Lyons, RM. Thrombolytic therapy for coronary artery thrombosis. *Bexar County Medical News*. 1988;41:10.
16. Spiro, TE, Christi M, Lyons, RM, Temaine MD, MacFarlaine DE, Blasier, RB. Efficacy & safety of enoxaparin for prevention of deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group. *Annals Internal Med*. 1994;121:81-89.
17. Adkins, DR, Salzman, D, Boldt, D, Kuhn, J, Irvin, R, Roodman, GD, Lyons, RM, Smith, L, Freytes, CO, Lemaistre, CF. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. *J Clin Onc*. 1994;12(9):1890-1901.
18. Heit, JA, Berkowitz, SD, Bona, R, Cabanas, V, Corson, JD, Elliott, CG, Lyons, RM. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery; a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. *Thrombosis and Haemostasis*. 1977;77(1):32-38.
19. Bussey, HI, Lyons, RM. Controversies in antithrombotic therapy for patients with mechanical heart valves. *Pharmacotherapy*. 1998;18(3):451-5.
20. Amato, MG, Bussey, HI, Farnett, LE, Lyons, RM. Acetaminophen and risk factors for excess anticoagulation with warfarin. *JAMA*. 1998;280(8):695-696.
21. Whitling, AM, Bussey, HI, Lyons, RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. *Archives of Internal Med*. 1998;158(19):2136-40.
22. George, JM, Raskob, GE, Vesely, Moore, D, Lyons, RM, Cobos, E, Towell, BL, Klug, PP, and Guthrie, TH. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. *Am J of Hematol*. 2003;74(3):161-9.
23. Lyons, RM, Andersen, JC, Frame, DG, et al. Evidence-based review of tinzaparin sodium and guidelines for administration. *Clin Adv in Hematol. and Onc*. 2003:Supplement;3-11.

24. Reese, AM, Farnett, LE, Lyons, RM, Patel, B, Morgan, L, Bussey, HI. Low dose vitamin K to augment anticoagulation control. *Pharmacotherapy*. 2005;25(12): 1746-1751.
25. Bussel, JB, Kuter, DJ, George, JN, McMillan, R, Aledort, LM, Conklin, GT, Lichtin, AE, Lyons, RM, Nieva, J, Wasser, JS, Wiznitzer, I, Kelly, R, Chen, CF, Nichol, J. Stimulating thrombopoiesis with AMG 531 improves platelet counts in patients with chronic immune thrombocytopenic purpura. *N Engl J Med*. 2006;355(16):1672-1681.
26. Deitcher, S, Kessler, C, Merli, G, Rigas, J, Lyons, R, Fareed, J. Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. *Clin Appl Thromb Hemost*. 2006;12(4):389-396.
27. Kantarjian, H, Giles, F, List, A, Lyons, R, Pierce, S, Leveque, J, Deuson, R. The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome (MDS). *Cancer*. 2007;109(9):1705-1714.
28. Kuter, D, Bussel, J, Lyons, R, Pullarkat, V, Gernsheimer, T, Senecal, F, Aledort, L, George, J, Kessler, C, Sanz, M, Liebman, H, Slovick, F, de Wolf, J, Bourgeois, E, Guthrie, T, Newland, A, Wasser, J, Hamburg, S, Grande, C, Lefrere, F, Lichtin, A, Tarantino, M, Terebelo, H, Viallard, J, Cuevas, F, Go, R, Henry, D, Redner, R, Rice, L, Schipperus, M, Guo, D, Nichol, J. Efficacy of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura: a Double-blind Randomized Controlled Trial. *Lancet*. 2008;371:395-403.
29. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Tomita, D, Dreiling, L. Phase 2, Single-Arm Trial to Evaluate the Effectiveness of Darbepoetin Alfa for Correcting Anaemic in Patients with Myelodysplastic Syndromes. *Br J Haematol*. 2008;142(3):379-393.
30. Stone, R, Sekeres, M, Garcia-Manero, G, Lyons, R. Recent Advances in Low- and Intermediate-1—Risk Myelodysplastic Syndrome: Developing a Consensus for Optimal Therapy. *Clin Adv Hem Onc*. 2008;6(12):1-16.
31. George, J, Mathias, S, Go, R, Guo, M, Henry, D, Lyons, R, Redner, R, Rice, L, Schipperus, M. Improved Quality of Life for Romiplostim-treated Patients with Chronic Immune Thrombocytopenic Purpura: Results From Two Randomized, Placebo-Controlled Trials. *Br J Haematol* 2009;144(3):409-415.
32. Lyons, R, Cosgriff, T, Modi, S, Gersh, R, Hainsworth, J, Cohn, A, McIntyre, H, Fernando, I, Backstrom, J, Beach, C. Hematologic Response to Three Alternative Dosing Schedules of Azacitadine in Patients with Myelodysplastic Syndromes. *J Clin Oncol*. 2009;27:11:1850-1856.

33. Bussel, J, Kuter, D, Pullarkat, V, Lyons, R, Guo, M, Nichol, J. Safety and Efficacy of Long-Term Treatment with Romiplostim in Thrombocytopenic Patients with ITP. *Blood* 2009;113:2161-2171.
34. Kantarjian, H, Erba, H, Cloaxton, D, Arellano, M, Lyons, R, Kovascovics, T, Gabrilove, J, Craig, M, Douer, D, Maris, M, Petersdorf, S, Shami, P, Yeager, A, Eckert, S, Abichandani, R, Faderl, S. Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults with Acute Myeloid Leukemia and Unfavorable Prognostic Factors. *J Clin Oncol.* 2010;28:4:549-555.
35. Di Bella, N, Taetle, R, Kolibaba, K, Boyd, T, Raju, R, Barrera, D, Cochran, E, Dien, P, Lyons, R, Schlegel, P, Vukelja, S, Boston, J, Boehm, K, Wang, Y, Asmar, L. Safety and Efficacy of Romiplostim in Patients with Lower-risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia. *J Clin Oncol.* 2010;28:3:437-444.
36. Kantarjian, H, Fenaux, P, Sekeres, M, Becker, P, Boruchov, A, Bowen, D, Hellstrom-Lindberg, E, Larson, R, Lyons, R, Muus, P, Shammo, J, Siegel, R, Hu, K, Franklin, J, Berger, D. Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma. *Blood.* 2010;115:3:475-480
37. Reynolds, C, DiBella, N, Lyons, R, Hyman, W, Richards, D, Robbins, G, Vellek, M, Boehm, K, Zhan, F, Asmar, L. A Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia. *Invest New Drugs.* 2011: Published online Sept. 16, 2011.
38. Claxton, D, Erba, H, Faderl, S, Arellano, M, Lyons, R, Kovascovics, R, Gabrilove, J, Huebner, D, Gandhi, P, Kantarjian, H. Outpatient Consolidation Treatment with Clofarabine in a Phase 2 Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML). *Leukemia and Lymphoma.* 2011: Published online Oct. 24, 2011.
39. Verstovsek, S, Mesa, R, Gotlib, J, Levy, R, Gupta, V, DiPersio, J, Catalano, J, Deininger, M, Miller, C, Silver, R, Talpaz, M, Winton, E, Harvey, J, Arcasoy, M, Hexner, E, Lyons, R, Paquette, R, Raza, A, Vaddi, K, Erickson-Viitanen, S, Koumenis, I, Sun, W, Sandor, V, Kantarjian, H. A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. *N Engl J Med.* Accepted for publication 2012.

ABSTRACTS

1. Lyons, RM, Goldenberg, GJ. Active transport of nitrogen mustard and choline by normal and leukemic human lymphoid cells. *Cancer Res.* 1972;32:1679-1685.
2. Lyons, RM, Majerus, PW. The effect of thrombin on protein phosphorylation in human platelets. *J Clin Invest.* 1974;53:48a..

3. Rutstein, JE, Holahan, JR, Lyons, RM, Pope, RM. Rheumatoid factor interference with tests for fibrin degradative products. *Clin Res.* 1978:26:25a.
4. Lyons, RM, Atherton, RM. Purification of the 40,000 mil weight phosphoprotein from thrombin treated human platelets. *Clin Res.* 1978:26:352a.
5. Lyons, RM and Shaw, JO. Interaction of Ca^{2+} and protein phosphorylation in the rabbit platelet release reaction. *Clin Res.* 1979:17:300a.
6. Shaw, JO, Lyons, RM. Ca^{2+} regulation of rabbit platelet activation initiated by basophil driven platelet activation factor (paf). *Blood.* 1979:54: 261a.
7. Lyons, RM. Adenosine 3': 5'' – monophosphate (CAMP) – binding proteins in the human platelet. *Clin Res.* 1979:27:745a.
8. Kessler, CM, Deitcher, SR, Merli, G, Rigas, J, Lyons, RM, and Cort, S. Low molecular weight heparin (enoxaparin) provides safe and effective antithrombotic therapy in active primary brain malignancies. *J Clin Oncology.* 2003:22:2980.
9. Deitcher, SR, Kessler, CM, Lyons, RM, Fareed, J. Treatment of venous thromboembolic events (VTE) in patients with active malignancy. *Blood.* 2003:102:270.
10. Deitcher, SR, Kessler, CM, Merli, G, Rigas, J, Lyons, RM, and Cort, S. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy. *J of Thrombosis and Haemostasis.* 2003:1:#OC194.
11. Kuter, D., Bussel, JB, Aledort, LM, George, J, Lyons, RM, Conklin, GT, Lichtin, AE, Nieva, J, Kelly, R, Chen, CF, Nichol, JL. A phase 2 placebo controlled study evaluating the platelet response and safety of weekly dosing with a novel thrombopoietic purpura (ITP). *Blood.* 2004:104(11):148:#511.
12. Gabrilove, J, Paquelte, R, Lyons, R, Mushtaq, C, Mun, Y, Drelling, L. Darbepoetin alfa for the treatment of anemia in patients with low risk myelodysplastic syndrome. *Supportive Care in Cancer.* Jun 2005:13:409a:# 02-007.
13. Bussel, J, Kuter, D, Aledort, L, George, J, Lyons, R, Wasser, J, Lichtin, A, Nieva, J, Chen, CF, Nichol, JL. An open-label study evaluating the safety and efficacy of long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura. *J of Thrombosis and Hemostasis.* 2005:3(suppl.1): #P0941.
14. Gabrilove J, Paquette R, Lyons R, Mushtaq C, Lam H, Dreiling L. Darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome. Poster presented at: 17th MASCC International Symposium; June 30-July 2, 2005; Geneva, Switzerland.

15. Gabrilove J, Paquette R, Lyons R, Mushtaq C, Sekeres M, Lam H, Dreiling L. Evaluating darbepoetin alfa for the treatment of anemia in patients with low-risk MDS. Poster presented at: 3rd International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, October 27-29, 2005, Washington, DC.
16. Bussel, J, Kuter, D, Aledort, L, George, J, Lyons, R, Wasser, J, Lichtin, A, Nieva, J, Kelly, R, Chen, CF, Nichol, JL. Safety and efficacy of long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura. *Blood*. 2005;106:11: #220.
17. Lyons, R, Cosgriff, T, Modi, S, Lintz, L, Beach, CL, Backstrom, JT. Azacitidine (Vldaza) treatment response assessed using three alternative dosing schedules in patients with myelodysplastic syndromes (MDS). *Blood*. 2005;106:11: #2517.
18. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Lam., H, Drelling., L. A phase 2, single-arm, open-label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome. *Blood*. 2005;106:11: #2541.
19. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Lam, H, Dreiling, L. Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes. *J of Clin Oncology*. 2006;24 (No. 18S):6579.
20. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Lam, H, Dreiling, L. Darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: interim results after 27/28 weeks. *J of Clin Onc*. 2006;24 (No. 18S):6564.
21. Anthony, S, Lyons, R, Cosgriff, T, Modi, S. Tranfusion independence assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. *J of Clin Onc*. 2006;24 (No. 18S):6574.
22. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Lam., H, Drelling., L. A phase 2, single-arm, open-label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome. Poster presented at: American College of Clinical Pharmacy. 2006. #2541.
23. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Lam, H, Drelling, L. Effectiveness and safety of darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome: interim results from the 13-week test period. Presented at the Academy of Managed Care Pharmacy.
24. Kuter, D, Bussel, J, George, J., Aledort, L, Lichtin, A, Lyons, R, Nieva, J, Wasser, J, Bourgeois, E, Kappers-Kune, M, Lefrere, F, Schipperus, R, Kelly, R, Christal, J, Guo, M, Nichol, J. Long-Term Dosing of AMG 531 in Throbocytopenic Patients with Immune Thrombocytopenic Purpura: 48 Week Update. *Blood*. 2006;108:11: (144a):#476.

25. Aledort, L, Lyons, R, Okano, G, Leveque, J. Retrospective matched Cohort Study of Immune Thrombocytopenic Purpura (ITP); Complications Related to Corticosteroid (CS) Use. *Blood*. 2006;108:11(940a):#3295.
26. Aledort, L, Lyons, R, Okano, G, Leveque, J. The Clinical and Direct Method Cost Burden of Splenectomy Among Managed Care Patients with Chronic Immune Thrombocytopenic Purpura (ITP). *Blood*. 2006;108:11(481-2b):#5536.
27. Kantarjian, H, Giles, F, List, A, Lyons, R, Pierce, S, Leveque, J, Deuson, R. The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome (MDS). *Blood*. 2006;108:11(739a): #2617.
28. Lyons, R, Cosgriff, T, Modi, S, McIntyre, H, Beach, C, Backstrom, J. Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes. *Blood*. 2006;108:11:#2662.
29. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Lam, H, Drelling, L. The Efficacy and Safety of Darbepoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results after 53/55 Weeks. *Blood*. 2006;108:11: #2671.
30. Lyons, R, Cosgriff, T, Modi, S, McIntyre, H, Beach, C, Backstrom, J. Tolerability and Hematologic Improvement Assessed Using Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes. *J of Clin Onc*. 2007;25 (No. 18S):#7083.
31. Gabrilove, R, Paquette, R, Lyons, R, Mushtaq, M, Sekeres, M, Tomita, D, Lillie, T. Baseline Predictors of Response to Treatment with Darbepoetin-alpha (DA) in Anemic Patients with Low-risk Myelodysplastic Syndrome (MDS). *J of Clin Onc*. 2007;25 (No. 18S):#7081.
32. Kantarjian, H, Giles, F, Fenaux, P, Beckyer, P, Boruchov, A, Bowen, D, Hellstrom-Lindberg, E, Larson, R, Lyons, R, Muus, P, The AMG531 in Myelodysplastic Syndrome Study Group. Evaluating Safety and Efficacy of AMG531 for the Treatment of Thrombocytopenic Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase ½ Study. *J of Clin Onc*. 2007;25 (No. 18S):#7032
33. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Tomita, D, Lillie, T. Final 53/55 Weeks Results From a Phase 2, Open-Label Study of the Efficacy and Safety of Darbepoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome. Presented at the 2007 Summer Hematology Oncology Pharmacy Association Conference, Denver, Co, June 14, 2007.
34. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Tomita, D, Lillie, T. Efficacy and Safety of Darbepoetin Alfa for Treating Anemia Patients with Low-Risk Myelodysplastic Syndrome. Presented at the 2007 Summer Meeting of the

American Society of Health-System Pharmacists, San Francisco, CA, June 24, 2007.

35. Kantarjian, H, Giles, F, List, A, Lyons, R, Sekeres, M, Pierce, S, Deuson, R, Leveque, J. Thrombocytopenia in MDS: Incidence and Impact. *Supportive Care in Cancer*. 2007;15:#P-148.
36. Kantarjian H, Giles, F, Fenaux, P, Becker, P, Boruchov, A, Bowen, D, Hellstrom-Lindberg, E, Larson, R, Lyons, R, Muus, P. Evaluating Safety and Efficacy of AMG 531 for the Treatment of Thrombocytopenic Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase 1/2 Study. *Supportive Care in Cancer*. 2007;15:#P-150.
37. Gabrilove, J, Paquette, R, Lyons, R, Mushtaq, C, Sekeres, M, Lam, H, Dreiling, L. The Efficacy and Safety of Darbopoetin Alfa for Treating Anemia in Low Risk Myelodysplastic Syndrome Patients: Results after 53/55 Weeks. *J of Supportive Oncology*. 2007;5:4(Suppl. 2): #14.
38. Kantarjian, H, Giles, F, List, A, Lyons, R, Price, S, Deuson, R, Leveque, J. The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome. *J of Supportive Oncology*. 2007;5:4(Suppl. 2): #74.
39. Kuter, D, Bussel, J, George, J, Aledort, L, Lichtin, A, Lyons, R, Nieva J, Wasser, J, Bourgeois, E, Kappers-Klunne, M, Lefrere, F, Schipperus, M, Kelly, R, Christal, J, Guo, M, Nichol, J. Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48 Week Update. *J of Supportive Oncology*. 2007;5:4(Suppl. 2): #78.
40. Kantarjian, H, Fenaux, P, Sekeres, M, Becker, P, Boruchov, A, Bowen, D, Larson, R, Lyons, R, Muus, P, Shammo, J, Ehrman, M, Hu, K, Nichol, J. Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients with Low Risk Myelodysplastic Syndrome (MDS): Update on Extended Treatment. *Blood*. 2007;110:11:#250.
41. George, J, Lyons, R, Cuevas, F, Go, R, Henry, D, Redner, R, Rice, L, Schipperus, M, Guo, M, Nichol, J. Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531. *Blood*. 2007;110:11:#1314.
42. Lyons, R, George, J, Grande C, Lefrere, F, Lichtin, A, Tarantino, M, Terebelo, H, Viallard, J, Guo, M, Nichol, J. Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP). *Blood*. 2007;110:11:#1300.
43. Lyons, R, Cosgriff, T, Modi, S, McIntyre, H, Fernando, I, Backstrom, J. Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS). *Blood*. 2007;110:11:#819.

44. Erba, H, Kantarjian, H, Claxton, D, Arellano, M, Lyons, R, Kovacsovics, T, Gabilove, J, Eckert, S, Abichandani, R, Faderl, S. Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit From Standard Induction Chemotherapy. *J of Clin Onc.* 2008;26: #7025 (May 20 suppl.)
45. Lyons, R, Cosgriff, T, Modi, S, McIntyre, H, Fernando, I, Backstrom, J, Beach, C. Rapid Onset of Effectiveness With Three Alternative Azacitidine (AZA) Dosing Regimens in Patients With Myelodysplastic Syndromes (MDS). *Haematologica.* 2008;93(s1):93:#0232.
46. Erba, H, Kantarjian, H, Claxton, D, Arellano, M, Lyons, R, Kovacsovics, T, Gabilove, J, Eckert, S, Abichandani, R, Faderl, S. Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy. *Blood.* 2008;112:#558.
47. Di Bella, N, Taetle, R, Kolibaba, K, Boyd, T, Raju, R, Barrera, D, Cochran, E, Dien P, Hakimian, D, Lyons, R, Schlegel, P, Vukelja, S, Boston, J, Boehm, K, Wang, Y, Asmar, L. Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma. *Blood.* 2008;112:#1572.
48. Reynolds, C, Di Bella, N, Lyons, R, Hyman, W, Lee, G, Richards, D, Robbins, G, Vallek, M, Boehm, K, Zhan, F, Asmar, L. Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab, Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia. *Blood.* 2008;112:#327.
49. George, J, Bussel, J, Lyons, R, Pullarkat, V, Redner, R, Terrell, D, Nie, K, Berger, D. Self-Injection of Romiplostim by Patients with Chronic Immune Thrombocytic Purpura (ITP). *Blood.* 2008;112:#4707.
50. Erba, H, Kantarjian, H, Claxton, D, Arellano, M, Lyons, R, Kovacsovics, T, Gabilove, J, Eckert, S, Faderl, S. Updated Remission Duration and Survival Results of Single-agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy Due to Unfavorable Baseline Risk Factor(s). *J Clin Oncol.* 2009;27:15s:#7062.
51. Lyons, R, Boccia, R, Macid, G, Mandanas, R, Wang, X, Lizambri, R, Berger, D. Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia. Presented at the 51st American Society of Hematology Annual Meeting, Dec. 5-9, 2009, New Orleans, LA.
52. Kantarjian, H, Lyons, R, Larson, R, Sekeres, M, Becker, P, Muus, P, Hu, K, Berger, D, Franklin, J. An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes. Presented at the 51st American Society of Hematology Annual Meeting, Dec. 5-9, 2009, New Orleans, LA

53. Lyons, R, Kosmo, M, Gnadhi, S, Liu, D, Chernoff, M, Dreisbach, L, Matei, C, Hu, K, Franklin, J, Berger, D. Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome Receiving Lenalidomide. Presented at the 51st American Society of Hematology Annual Meeting, Dec. 5-9, 2009, New Orleans, LA
54. Gabrilove, J, Faderl, S, Erba, H, Claxton, D, Arellano, M, Lyons, R, Kovacsovics, T, Eckert, S, Huebner, D, Kantarjian, H. Complete Response to Clofarabine is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia and Unfavorable Prognostic Factors. Presented at the 51st American Society of Hematology Annual Meeting, Dec. 5-9, 2009, New Orleans, LA
55. Erba, H, Faderl, S, Claxton, D, Arellano, M, Lyons, R, Kovacsovics, T, Gabrilove, J, Eckert, S, Huebner, D, Kantarjian, H. Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia Who are ≥ 70 , Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders, or 2 or More Unfavorable Prognostic Factors. Presented at the 51st American Society of Hematology Annual Meeting, Dec. 5-9, 2009, New Orleans, LA
56. Garcia-Manero, G, Marek, B, Lyons, R, Martinez-Lopez, N, Paley, C, Greenberg, P. Clinical Parameters in 391 Iron-Overloaded Patients with Lower-Risk MDS Enrolled in a Prospective, Non-Interventional Multicenter Registry. *Blood* 2009;114#4834.
57. Claxton, D, Myers, T, Erba, H, Faderl, S, Arrellano, M, Lyons, R, Kovacsovics, T, Gabrilove, J, Warnock, C, Kantarjian, H. Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia. *Blood* 2009;114:#4162.
58. Faderl, S, Erba, H, Claxton, D, Arellano, M, Lyons, R, Kovacsovics, T, Gabrilove, J, Anderson, E, Barry, E, Kantarjian, H. Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities. *Blood* 2009;114:#4155.
59. Kuter, D, Bussel, J, Newland, A, Wasser, J, Lyons, R, George, J, Macik, G, Nie, K, Jun, S. Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. *Blood* 2010;116:#68.
60. Fenaux, P, Kantarjian, H, Lyons, R, Larson, R, Sekeres, M, Becker, P, Muus, P, Jia, C, Yang, A. Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS). *Blood* 2010;116:#1885.

61. Fenaux, P, Kantarjian, H, Lyons, R, Larson, R, Sekeres, M, Becker, P, Muus, P, Jia, C, Yang, A. Update of an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients With Myelodysplastic Syndromes (MDS). *Leuk Res* 2011;35:1:S84:#215. Presented at the 11th International Symposium on Myelodysplastic Syndromes, Edinburgh, Scotland, May 18-21, 2011.
62. Garcia-Manero, G, Marek, B, Lyons, R, Martinez-Lopez, N, Esposito, J, Paley, C, DiBella, N. A 12-Month Follow-Up of an Ongoing Prospective, Non-Interventional, Multicenter Registry in Iron Overloaded Patients with Lower-Risk Myelodysplastic Syndromes. *Leuk Res* 2011;35:1:S85:#217. Presented at the 11th International Symposium on Myelodysplastic Syndromes, Edinburgh, Scotland, May 18-21, 2011.
63. Verstovsek, S, Mesa, R, Gotlib, J, Levy, R, Gupta, V, DiPersio, J, Catalano, J, Deininger, M, Miller, C, Silver, R, Talpaz, M, Winton, E, Harvey, J, Arcasoy, M, Hexner, E, Lyons, R, Paquette, R, Raza, A, Vaddi, K, Erickson-Viitanen, S, Koumenis, I, Sun, W, Sandor, V, Kantarjian, H. Results of Comfort-I, A Randomized, Double-Blind Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib (INCB018424) Versus Placebo for Patients with Myelofibrosis. Presented at the 16th Congress of the European Hematology Association in London, UK, June 9-12, 2011.
64. Lyons, R, Marek, B, Sharma, S, Paley, C, Esposito, J, Garbo, L, DiBella, N, Garcia-Manero, G. 24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients. Accepted for poster presentation, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.
65. Wasser, J, Boccia, R, Lyons, R, Mandanas, R, Pabinger, I, Michel, M, Viallard, J, Wang, X, Lizambri, R. Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients With Immune Thrombocytopenia (ITP). Accepted for poster presentation, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.
66. Fenaux, P, Kantarjian, H, Muus, P, Lyons, R, Larson, R, Kerem, S, Becker, P, Jia, C, Yang, Allen, Guan, X. Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS). Accepted for poster presentation, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.
67. Raza, A, Galili, N, Mulford, D, Smith, S, Brown, G, Meng, L, Steensma, D, Lyons, R, Boccia, R, Sekeres, M, Garcia-Manero, G, Mesa, R. Phase I Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra[®], TLK199) in Combination with Lenalidomide (Revlimid[®]) in Patients with Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Accepted for poster presentation, 53rd

American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.

68. Verstovsek, S, Mesa, R, Gotlib, J, Levy, R, Gupta, V, DiPersio, J, Catalano, J, Deininger, M, Miller, C, Silver, R, Talpaz, M, Winton, E, Harvey, J, Arcasoy, M, Hexner, E, Lyons, R, Paquette, R, Raza, A, Vaddi, K, Erickson-Viitanen, S, Sun, W, Sandor, V, Kantarjian, H. Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-1. Accepted for oral presentation, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.

69. Verstovsek, S, Mesa, R, Gotlib, J, Levy, R, Gupta, V, DiPersio, J, Catalano, J, Deininger, M, Miller, C, Silver, R, Talpaz, M, Winton, E, Harvey, J, Arcasoy, M, Hexner, E, Lyons, R, Paquette, R, Raza, A, Vaddi, K, Erickson-Viitanen, S, Sun, W, Sandor, V, Kantarjian, H. Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-1). Accepted for publication, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.